Key Highlights
- David A. Green joins SeaStar Medical as Chief Financial Officer, effective January 10, 2024, bringing over 25 years of healthcare sector experience.
- Caryl Baron will continue her role in the company as Vice President of Finance, after serving as Interim CFO since October 2022.
- SeaStar Medical is preparing for its first commercial launch of the Selected Cytopheretic Device Pediatric (SCD-PED), a groundbreaking solution for hyperinflammation.
- Mr. Green’s experience includes roles at Prolacta Bioscience, Aytu BioPharma, Intarcia Therapeutics, Catheter Connections, and Specialized Health Products International.
- SeaStar Medical specializes in innovative therapies to mitigate the impact of excessive inflammation on vital organs.
Source: Globe Newswire
Notable Quotes
- “David’s extensive financial experience at public medical device and therapeutics companies will be highly valuable as we work to bring our groundbreaking solutions to those with devastating hyperinflammation,” – Eric Schlorff, CEO at SeaStar Medical
- “SeaStar Medical’s cell-directed extracorporeal therapy holds potential in multiple high-value indications to stop the threat of a dysregulated inflammatory response,” – David A. Green, CFO at SeaStar Medical
SoH's Take
The appointment of David A. Green as CFO of SeaStar Medical is a strategic move that aligns with the company’s imminent commercial ventures, particularly the launch of SCD-PED. Green’s extensive background in finance within the healthcare sector, especially in companies undergoing significant transitions like public offerings and mergers, is an asset to SeaStar Medical’s growth trajectory. His prior experience in guiding companies through critical financial phases will be instrumental in SeaStar’s journey, especially in the highly competitive and regulatory-intensive medical device market. As the company advances its innovative therapies for hyperinflammation, having a CFO with a strong track record in financial stewardship and strategic growth will likely bolster investor confidence and facilitate smoother entry into new markets.
